Your browser doesn't support javascript.
loading
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva, Ines; Ahmed, Tasnia; Reijers, Irene L M; Weppler, Alison M; Betof Warner, Allison; Patrinely, James Randall; Serra-Bellver, Patricio; Allayous, Clara; Mangana, Joanna; Nguyen, Khang; Zimmer, Lisa; Trojaniello, Claudia; Stout, Dan; Lyle, Megan; Klein, Oliver; Gerard, Camille L; Michielin, Olivier; Haydon, Andrew; Ascierto, Paolo A; Carlino, Matteo S; Lebbe, Celeste; Lorigan, Paul; Johnson, Douglas B; Sandhu, Shahneen; Lo, Serigne N; Blank, Christian U; Menzies, Alexander M; Long, Georgina V.
Afiliación
  • Pires da Silva I; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Westmead Hospital, Sydney, NSW, Australia; Blacktown Hospital, Sydney, NSW, Australia.
  • Ahmed T; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia.
  • Reijers ILM; Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Weppler AM; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.
  • Betof Warner A; Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
  • Patrinely JR; Vanderbilt University Medical Center, Nashville, TN, USA.
  • Serra-Bellver P; The Christie NHS Foundation Trust, Manchester, UK.
  • Allayous C; AP-HP Dermatology, INSERM U976, Université de Paris, Saint Louis Hospital, Paris, France.
  • Mangana J; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
  • Nguyen K; Westmead Hospital, Sydney, NSW, Australia; Blacktown Hospital, Sydney, NSW, Australia.
  • Zimmer L; Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Trojaniello C; Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Napoli, Italy.
  • Stout D; Alfred Hospital, Monash University, Melbourne, VIC, Australia.
  • Lyle M; Cairns Hospital, James Cook University, Cairns, QLD, Australia.
  • Klein O; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.
  • Gerard CL; Oncology Department, Lausanne University Hospital, Lausanne, Switzerland.
  • Michielin O; Oncology Department, Lausanne University Hospital, Lausanne, Switzerland.
  • Haydon A; Alfred Hospital, Monash University, Melbourne, VIC, Australia.
  • Ascierto PA; Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Napoli, Italy.
  • Carlino MS; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Westmead Hospital, Sydney, NSW, Australia; Blacktown Hospital, Sydney, NSW, Australia.
  • Lebbe C; AP-HP Dermatology, INSERM U976, Université de Paris, Saint Louis Hospital, Paris, France.
  • Lorigan P; The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK.
  • Johnson DB; Vanderbilt University Medical Center, Nashville, TN, USA.
  • Sandhu S; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.
  • Lo SN; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia.
  • Blank CU; Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Menzies AM; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia; Mater Hospital, Sydney, NSW, Australia.
  • Long GV; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia; Mater Hospital, Sydney, NSW, Australia. Electronic address: georgina.long@sydney.edu.au.
Lancet Oncol ; 22(6): 836-847, 2021 06.
Article en En | MEDLINE | ID: mdl-33989557
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptor de Muerte Celular Programada 1 / Ipilimumab / Inhibidores de Puntos de Control Inmunológico / Melanoma Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Australia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptor de Muerte Celular Programada 1 / Ipilimumab / Inhibidores de Puntos de Control Inmunológico / Melanoma Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Australia